APA Citation

Abrisqueta Costa, P., González Barca, E., Ferrà, C., Rios-Herranz, E., Fernández de la Mata, M., Delgado, J. (. G., . . . Bosch Albareda, F. (2024). Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).

Chicago Style Citation

Abrisqueta Costa, Pau, et al. Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL): GELLC-7 Trial From the Spanish Group of CLL (GELLC). 2024.

MLA Citation

Abrisqueta Costa, Pau, et al. Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL): GELLC-7 Trial From the Spanish Group of CLL (GELLC). 2024.

Warning: These citations may not always be 100% accurate.